Prediction of Insufficient Beta-Lactam Concentrations in Extracorporeal Membranous Oxygenation Patients.
ECMO
antibiotics
critical illness
therapeutic drug monitoring
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
25 Oct 2021
25 Oct 2021
Historique:
received:
02
10
2021
revised:
12
10
2021
accepted:
19
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The aim of this study was to identify predictors of insufficient beta-lactam concentrations in patients undergoing extracorporeal membrane oxygenation (ECMO). Retrospective analysis of all patients receiving ECMO support and treated with ceftazidime or cefepime (CEF), piperacillin/tazobactam (TZP), or meropenem (MEM). Trough drug concentrations (C A total of 222 C Insufficient broad-spectrum beta-lactam concentrations were observed in 12% of drug measurement during ECMO therapy. Higher than recommended drug regimens could be considered in the very early phase of therapy and in those patients with augmented renal clearance and with less severe organ dysfunction.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to identify predictors of insufficient beta-lactam concentrations in patients undergoing extracorporeal membrane oxygenation (ECMO).
METHODS
METHODS
Retrospective analysis of all patients receiving ECMO support and treated with ceftazidime or cefepime (CEF), piperacillin/tazobactam (TZP), or meropenem (MEM). Trough drug concentrations (C
RESULTS
RESULTS
A total of 222 C
CONCLUSIONS
CONCLUSIONS
Insufficient broad-spectrum beta-lactam concentrations were observed in 12% of drug measurement during ECMO therapy. Higher than recommended drug regimens could be considered in the very early phase of therapy and in those patients with augmented renal clearance and with less severe organ dysfunction.
Identifiants
pubmed: 34835344
pii: microorganisms9112219
doi: 10.3390/microorganisms9112219
pmc: PMC8625763
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Microorganisms. 2021 Jun 16;9(6):
pubmed: 34208553
ASAIO J. 2015 Jan-Feb;61(1):31-6
pubmed: 25303799
BMC Pharmacol Toxicol. 2014 Apr 14;15:21
pubmed: 24731745
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530848
ASAIO J. 2016 Jan-Feb;62(1):80-6
pubmed: 26579980
Perfusion. 2020 May;35(1_suppl):38-49
pubmed: 32397884
Crit Care Med. 1998 Nov;26(11):1793-800
pubmed: 9824069
Expert Rev Anti Infect Ther. 2020 Jan;18(1):27-35
pubmed: 31755789
J Antimicrob Chemother. 2021 Apr 13;76(5):1242-1249
pubmed: 33569597
Int J Antimicrob Agents. 2021 Dec;58(6):106466
pubmed: 34688834
Crit Care. 2014 Dec 12;18(6):565
pubmed: 25636084
Int J Antimicrob Agents. 2015 Mar;45(3):278-82
pubmed: 25542059
Anaesth Crit Care Pain Med. 2019 Oct;38(5):493-497
pubmed: 30831307
Crit Care. 2010;14(4):R126
pubmed: 20594297
Minerva Anestesiol. 2015 May;81(5):497-506
pubmed: 25220556
Intensive Care Med. 2020 Jun;46(6):1127-1153
pubmed: 32383061
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Int J Antimicrob Agents. 2013 Nov;42(5):422-8
pubmed: 23993066
ASAIO J. 2020 Feb;66(2):141-145
pubmed: 30864968
Antimicrob Agents Chemother. 2013 Feb;57(2):708-15
pubmed: 23147743
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29987138
Clin Biochem. 2010 Apr;43(6):589-98
pubmed: 20036226
Crit Care. 2020 Nov 25;24(1):664
pubmed: 33239110
Curr Infect Dis Rep. 2018 Apr 4;20(5):9
pubmed: 29619607
Neurocrit Care. 2018 Aug;29(1):94-104
pubmed: 29560599